光学基因组图谱市场－全球产业规模、份额、趋势、机会及预测（按产品、应用、最终用户、地区和竞争格局划分，2021-2031年）

全球光学基因组图谱市场预计将从 2025 年的 2.7 亿美元成长到 2031 年的 9.7 亿美元，复合年增长率为 23.76%。

光学基因组图谱技术是一种非定序技术，它分析极长的DNA分子，以超越传统细胞遗传学方法的分辨率检测结构变异。该市场的主要驱动因素是临床上对骨髓恶性肿瘤精准诊断日益增长的需求，以及实验室向整合各种传统工作流程的数位化检测方法的策略转型。这些因素使医疗机构能够更有效率地产生全面的基因组图谱，从而改善患者照护并缩短获得重要诊断结果的时间。

儘管临床获益显着，但设备的巨额初始投资以及分析所需的大量生物资讯资源，对小规模病理中心而言，是推广应用该技术的重大障碍。欧洲血液学会2024年发表的数据显示，与标准通讯协定相比，采用光学基因组图谱的临床研究可使约18%的髓系肿瘤病例的风险分层得到改善。这项数据固然反映了该平台的诊断优势，但也凸显了高阶数据解读的必要性，这可能会减缓其在更广泛的市场成长。

市场驱动因素

光学基因组图谱技术在癌症诊断和肿瘤监测领域的应用不断拓展，尤其是在骨髓恶性肿瘤，正从根本上改变全球光学基因组图谱市场。随着临床医生日益寻求详细的基因组图谱以指南精准医疗，拓展光学基因组图谱技术的功能，使其超越传统技术的简单一致性，成为关键目标。该技术能够识别次世代定序常常遗漏的隐匿性结构突变，从而为复杂的白血病和淋巴瘤病例提供重要的预后信息，因此正迅速得到广泛应用。美国国家医学图书馆于2025年4月引用的一项研究表明，与标准细胞遗传学评估相比，光学基因组图谱技术在15%的骨髓恶性肿瘤病例中检测到额外的具有临床意义的一级突变，这凸显了其在改善患者管理方面的关键作用。

推动市场扩张的第二个主要因素是传统细胞遗传学方法（例如核型分析和萤光原位杂合反应(FISH)）的系统性替代品。实验室正积极将分散的工作流程整合到单一的高解析度数位检测中，从而提高操作效率并降低与手动方法相关的成本。这种从类比细胞遗传学转变为数位细胞遗传学的比例得益于检测耗材需求的成长。 2025年1月，Bionano Genomics公司报告称，2024年第四季奈米通道阵列流动池的销量为8,058个。此外，同月发布的初步报告显示，全球光学基因组作图系统的部署量已增加至371套，显示实验室正在持续转型为此平台。

市场挑战

光学基因组图谱技术广泛应用的主要障碍在于仪器设备的巨额资本投入，以及数据分析所需的大规模生物资讯资源。许多诊断实验室，尤其是小规模区域中心，面临严重的预算限制，难以承担高昂的初始硬体成本和持续的专用数位基础设施维护费用。因此，这种经济负担使得该技术的应用主要局限于资金雄厚的学术机构和大规模参考实验室，难以实现基于大检体量的商业化市场规模。

这些经济和技术挑战的影响体现在近期的市场普及率数据中。根据美国病理学家协会 (CAP) 2024 年的调查数据，仅有 9.4% 的参与实验室成功实施了光学基因组图谱技术。如此低的普及率表明，市场仍然高度分散，大多数病理服务机构无法将平台整合到其日常工作流程中。因此，高进入门槛直接限制了全球市场的收入成长潜力，使这项技术局限于小众领域，而无法扩展到常规临床实践中。

市场趋势

光学基因组图谱技术在发现未确诊的罕见遗传疾病方面正发挥着重要作用，弥补了传统疾病标准治疗方法的局限性。临床医师正积极采用这项技术，在进行EXOME或基因测序后仍未确诊的患者中发现致病性结构变异，从而逐步缩短诊断流程。该平台作为生殖系分析的主要工具，其应用范围正从肿瘤学扩展到医学遗传学领域，在医学遗传学中，检测隐匿突变至关重要。根据美国国家医学图书馆引用的2025年11月报告《光学基因组图谱技术的现况与未来应用》，调查数据显示，108家实验室计画在24个月内将此技术应用于临床试验，这主要是由于其在先天性疾病和生殖系突变分析方面的效用。

同时，将光学基因组图谱技术引入产前和产后生殖检测领域，正开闢新的市场商业性途径。各实验室正在检验该平台在识别胎儿样本和胚胎着床前胚胎中的平衡易位和复杂染色体重排方面的有效性，其分辨率优于染色体微阵列技术。这项技术对于提高体外受精（IVF）的成功率和准确评估復发性流产的风险至关重要，并推动了癌症诊断以外其他领域的成长。 Bionano Genomics公司于2025年3月发布的《2024年第四季及全年财务报告》特别强调了该应用日益增长的科学支持。报告显示，2024年光学基因组图谱相关论文总数达336篇，较上年增加19%。这一增长主要得益于产前和产后遗传疾病研究的显着进展。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球光学基因组图谱市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（耗材与设备）
  • 依应用领域（基因组组装、结构变异检测、微生物菌株分型、单倍型分析等）
  • 按最终用户（研究/学术机构、生物技术/製药公司、临床检查室、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美光学基因组图谱市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲光学基因组图谱市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区光学基因组图谱市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲光学基因组图谱市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美光学基因组图谱市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球光学基因组图谱市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Bionano Genomics, Inc.
• Nucleome Informatics Private Limited
• Nabsys, Inc.
• PerkinElmer, Inc.
• SourceBio International Limited
• MedGenome Labs Private Limited
• Cerba HealthCare
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Oxford Nanopore Technologies plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Optical Genome Mapping Market is projected to expand from USD 0.27 Billion in 2025 to USD 0.97 Billion by 2031, registering a CAGR of 23.76%. As a non-sequencing technology, optical genome mapping analyzes ultra-long DNA molecules to detect structural variations with a resolution exceeding traditional cytogenetic techniques. The market is primarily driven by the rising clinical need for accurate diagnosis of hematologic malignancies and a strategic shift within laboratories to merge various legacy workflows into a unified digital assay. These drivers enable medical facilities to generate comprehensive genomic profiles more efficiently, improving patient care and shortening the time required for critical diagnostic results.

Despite its evident clinical benefits, the substantial initial capital investment for equipment and the considerable bioinformatic resources needed for analysis pose significant hurdles to adoption in smaller pathology centers. Data presented by the European Hematology Association in 2024 revealed that clinical research using optical genome mapping improved risk stratification in roughly 18 percent of myeloid neoplasm cases compared to standard protocols. While this figure highlights the platform's diagnostic advantages, it also emphasizes the sophisticated data interpretation requirements that could slow down broader market growth.

Market Driver

Expanding applications in cancer diagnostics and oncology research, particularly for hematological malignancies, are fundamentally transforming the Global Optical Genome Mapping Market. As clinicians increasingly demand detailed genomic profiles to inform precision medicine, extending the capabilities of optical genome mapping beyond mere agreement with legacy techniques has become a key objective. The technology is rapidly being adopted for its capacity to identify hidden structural variants often overlooked by next-generation sequencing, providing vital prognostic information for complex cases of leukemia and lymphoma. According to a study referenced by the National Library of Medicine in April 2025, optical genome mapping detected additional clinically significant Tier 1 variants in 15 percent of hematological malignancy cases compared to standard cytogenetic evaluations, confirming its critical role in enhancing patient management.

A second major factor propelling market momentum is the systematic replacement of traditional cytogenetic methods like karyotyping and fluorescence in situ hybridization (FISH). Laboratories are actively merging fragmented workflows into this single, high-resolution digital assay to boost operational efficiency and alleviate the cost pressures of labor-intensive manual techniques. This shift from analog to digital cytogenetics is underscored by the rising demand for testing consumables; Bionano Genomics reported in January 2025 the sale of 8,058 nanochannel array flowcells for the fourth quarter of 2024. Furthermore, the company's preliminary report from the same month indicated that the global installed base had grown to 371 optical genome mapping systems, reflecting the increasing operational transition toward this platform.

Market Challenge

The significant capital investment required for instrumentation, coupled with the extensive bioinformatic resources necessary for data analysis, serves as a major obstacle to the widespread uptake of optical genome mapping. Many diagnostic laboratories, particularly smaller community centers, face strict budget limitations that make it difficult to justify the high upfront hardware costs and the continuous expense of specialized digital infrastructure. Consequently, this financial strain limits the technology's availability primarily to well-resourced academic institutions and large reference laboratories, hindering the market from achieving commercial scale based on high sample volumes.

The effect of these economic and technical challenges is reflected in recent adoption figures. Survey data from the College of American Pathologists in 2024 revealed that only 9.4 percent of participating laboratories had successfully integrated optical genome mapping. This low rate of utilization demonstrates that the market remains highly fragmented, with most pathology providers unable to incorporate the platform into their regular workflows. As a result, high entry barriers directly constrain the potential revenue expansion of the global market by relegating the technology to a niche role rather than enabling its progression into routine clinical practice.

Market Trends

A pivotal trend is the application of optical genome mapping to resolve undiagnosed rare genetic diseases, addressing the shortcomings of standard-of-care methods for constitutional disorders. Clinicians are increasingly adopting this technology to uncover pathogenic structural variants in patients who remain without a diagnosis following exome or genome sequencing, thereby concluding distinct diagnostic odysseys. This transition toward utilizing the platform as a primary instrument for germline analysis is extending its reach beyond oncology into medical genetics departments, where detecting cryptic variants is essential. According to the 'Current and Future Utilization of Optical Genome Mapping' report cited by the National Library of Medicine in November 2025, survey data showed that 108 laboratories intend to adopt the technology clinically within 24 months, largely driven by its utility in constitutional and germline analysis.

Simultaneously, the introduction of optical genome mapping into prenatal and postnatal reproductive testing is creating a new commercial pathway for the market. Laboratories are validating the platform to identify balanced translocations and complex chromosomal rearrangements in fetal samples and preimplantation embryos, offering resolution superior to that of chromosomal microarrays. This capability is vital for enhancing in-vitro fertilization success rates and providing precise risk assessments for recurrent pregnancy loss, fueling growth in a segment distinct from cancer diagnostics. The increasing scientific support for this application is highlighted by Bionano Genomics' 'Fourth Quarter and Full-Year 2024 Results' from March 2025, which noted that the total number of optical genome mapping publications rose to 336 in 2024, a 19 percent annual increase characterized by significant research growth in prenatal and postnatal genetic disorders.

Key Market Players

• Bionano Genomics, Inc.
• Nucleome Informatics Private Limited
• Nabsys, Inc.
• PerkinElmer, Inc.
• SourceBio International Limited
• MedGenome Labs Private Limited
• Cerba HealthCare
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Oxford Nanopore Technologies plc

Report Scope

In this report, the Global Optical Genome Mapping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Optical Genome Mapping Market, By Product

• Consumables v/s Instruments

Optical Genome Mapping Market, By Application

• Genome Assembly
• Structural Variation Detection
• Microbial Strain Typing
• Haplotype Phasing
• Others

Optical Genome Mapping Market, By End User

• Research and Academic Institutions
• Biotechnology & Pharmaceutical Companies
• Clinical Laboratories
• Others

Optical Genome Mapping Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Optical Genome Mapping Market.

Available Customizations:

Global Optical Genome Mapping Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Optical Genome Mapping Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Consumables v/s Instruments)
  • 5.2.2. By Application (Genome Assembly, Structural Variation Detection, Microbial Strain Typing, Haplotype Phasing, Others)
  • 5.2.3. By End User (Research and Academic Institutions, Biotechnology & Pharmaceutical Companies, Clinical Laboratories, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Optical Genome Mapping Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Optical Genome Mapping Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Optical Genome Mapping Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Optical Genome Mapping Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Optical Genome Mapping Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Optical Genome Mapping Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. France Optical Genome Mapping Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Optical Genome Mapping Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Optical Genome Mapping Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Optical Genome Mapping Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia Pacific Optical Genome Mapping Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Optical Genome Mapping Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Optical Genome Mapping Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Optical Genome Mapping Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Optical Genome Mapping Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Optical Genome Mapping Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. Middle East & Africa Optical Genome Mapping Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Optical Genome Mapping Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Optical Genome Mapping Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Optical Genome Mapping Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. South America Optical Genome Mapping Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Optical Genome Mapping Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Optical Genome Mapping Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Optical Genome Mapping Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Optical Genome Mapping Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bionano Genomics, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Nucleome Informatics Private Limited
• 15.3. Nabsys, Inc.
• 15.4. PerkinElmer, Inc.
• 15.5. SourceBio International Limited
• 15.6. MedGenome Labs Private Limited
• 15.7. Cerba HealthCare
• 15.8. Illumina, Inc.
• 15.9. Thermo Fisher Scientific Inc.
• 15.10. Oxford Nanopore Technologies plc

16. Strategic Recommendations

17. About Us & Disclaimer